Exabis Library
Welcome to the e-CCO Library!
OP17: Impact of phenotypic and genetic factors on Crohn’s Disease evolution in a cohort of 13,926 patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP17: Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP18 Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: The SuPREMe-CD study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP18: Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP18: Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction treatment versus anti-TNF without surgery (PISA II) - A patient preference RCT
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP19 Perinatal factors do not affect paediatric inflammatory bowel disease risk: A Scottish Nationwide Cohort study using administrative health data 1981–2017
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP19: Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trials
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP19: Disease course and treatment outcomes of early resected Crohn's Disease patients: A Danish nationwide cohort study from 1997 to 2015
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP19: Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP20 The gut microbiota during biological therapy for inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP20: The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM